American Association for Cancer Research
Browse
21598290cd181494-sup-214162_2_supp_5551248_ps8cdj.docx (109.18 kB)

Supplementary Data from Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers

Download (109.18 kB)
journal contribution
posted on 2023-04-03, 22:40 authored by Maria R. Parkhurst, Paul F. Robbins, Eric Tran, Todd D. Prickett, Jared J. Gartner, Li Jia, Gabriel Ivey, Yong F. Li, Mona El-Gamil, Almin Lalani, Jessica S. Crystal, Abraham Sachs, Eric Groh, Satyajit Ray, Lien T. Ngo, Scott Kivitz, Anna Pasetto, Rami Yossef, Frank J. Lowery, Stephanie L. Goff, Winifred Lo, Gal Cafri, Drew C. Deniger, Parisa Malekzadeh, Mojgan Ahmadzadeh, John R. Wunderlich, Robert P.T. Somerville, Steven A. Rosenberg

Supplementary Materials and Methods

Funding

Center for Clinical Research

NCI

NIH

History

ARTICLE ABSTRACT

Immunotherapies can mediate regression of human tumors with high mutation rates, but responses are rarely observed in patients with common epithelial cancers. This raises the question of whether patients with these common cancers harbor T lymphocytes that recognize mutant proteins expressed by autologous tumors that may represent ideal targets for immunotherapy. Using high-throughput immunologic screening of mutant gene products identified via whole-exome sequencing, we identified neoantigen-reactive tumor-infiltrating lymphocytes (TIL) from 62 of 75 (83%) patients with common gastrointestinal cancers. In total, 124 neoantigen-reactive TIL populations were identified, and all but one of the neoantigenic determinants were unique. The results of in vitro T-cell recognition assays demonstrated that 1.6% of the gene products encoded by somatic nonsynonymous mutations were immunogenic. These findings demonstrate that the majority of common epithelial cancers elicit immune recognition and open possibilities for cell-based immunotherapies for patients bearing these cancers. TILs cultured from 62 of 75 (83%) patients with gastrointestinal cancers recognized neoantigens encoded by 1.6% of somatic mutations expressed by autologous tumor cells, and 99% of the neoantigenic determinants appeared to be unique and not shared between patients.This article is highlighted in the In This Issue feature, p. 983

Usage metrics

    Cancer Discovery

    Licence

    Exports